- Home
- KSS vs DNTH Comparison
KSS vs DNTH Comparison
Compare KSS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KSS | DNTH |
|---|---|---|
| Founded | 1962 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KSS | DNTH |
|---|---|---|
| Price | $12.01 | $79.02 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $15.31 | ★ $121.90 |
| AVG Volume (30 Days) | ★ 4.7M | 1.0M |
| Earning Date | 03-10-2026 | 03-09-2026 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.79 | $58.85 |
| P/E Ratio | $9.24 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.04 | $13.37 |
| 52 Week High | $25.22 | $88.45 |
Technical Indicators
Market Signals| Indicator | KSS | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 19.12 | 70.83 |
| Support Level | $10.33 | $34.83 |
| Resistance Level | $16.95 | $88.45 |
| Average True Range (ATR) | 0.91 | 4.92 |
| MACD | -0.29 | 1.18 |
| Stochastic Oscillator | 1.72 | 74.07 |
Price Performance
Historical ComparisonAbout KSS Kohl's Corporation
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.